Germline or somatic mutations in the BRCA1 or BRCA2 gene have prognostic value in ovarian cancer since ovarian cancer patients with BRCA1/2 mutations are reported to have a better response to platinum-based treatment [2] and subsequently a longer survival duration than patients without such mutations [3-5]. The gene discussed is BRCA2; the disease is ovarian carcinoma.